Canaccord Genuity Gives Buy Rating to Watson Pharmaceuticals Incorporated (WPI)
Shares of Watson Pharmaceuticals Incorporated opened at 71.00 on Tuesday. Watson Pharmaceuticals Incorporated has a 52 week low of $55.00 and a 52 week high of $76.47. The company has a market cap of $9.046 billion and a P/E ratio of 33.36.
Watson Pharmaceuticals Incorporated last announced its earnings results on Monday, April 30th. The company reported $1.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.04. The company’s revenue for the quarter was up 73.9% on a year-over-year basis. On average, analysts predict that Watson Pharmaceuticals Incorporated will post $1.34 earnings per share next quarter.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Watson Pharmaceuticals Incorporated in a research note to investors on Tuesday, May 1st. They now have a $79.00 price target on the stock. Separately, analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Watson Pharmaceuticals Incorporated from $60.00 to $81.00 in a research note to investors on Tuesday, May 1st. They now have a “hold” rating on the stock. Finally, analysts at Bank of America (NYSE: BAC) raised their price target on shares of Watson Pharmaceuticals Incorporated from $72.00 to $92.00 in a research note to investors on Friday, April 27th. They now have a “buy” rating on the stock.
Watson Pharmaceuticals, Inc. (Watson) is an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products.